Economic evaluations of neuraminidase inhibitors to control influenza. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Expert Review of Pharmacoeconomics and Outcomes Research Année : 2003

Economic evaluations of neuraminidase inhibitors to control influenza.

Résumé

Up to 10% of individuals present influenza-like illness each year. Neuraminidase inhibitors significantly reduce the median duration of influenza symptoms by 1.38 days and median time to return to normal activities by 0.9 days in adults. This review presents the economic evaluations of neuraminidase inhibitors in adults. The choice of key parameter estimates in cost-effectiveness and cost-benefit analysis is sensitive to the perspective of analysis: healthcare payer or societal, including productivity gains. This review discusses, among other key parameters, the proportion of influenza-like illness due to the influenza virus (targeted by neuraminidase inhibitors and influenza vaccine), and the measure of health benefits by either quality-adjusted life years gained or willingness-to-pay for a day of symptoms averted. Overall, neuraminidase inhibitors are worth their costs and do not challenge annual influenza vaccination but should be seen as a complementary option to reduce the burden of influenza.
Fichier principal
Vignette du fichier
Review_of_economic_evaluations_of_NA-inh_2.pdf (420.23 Ko) Télécharger le fichier
inserm-00636182_edited.pdf (186.65 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-00636182 , version 1 (27-10-2011)

Identifiants

Citer

Michaël Schwarzinger, Karine Lacombe, Fabrice Carrat. Economic evaluations of neuraminidase inhibitors to control influenza.. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3 (2), pp.147-58. ⟨10.1586/14737167.3.2.147⟩. ⟨inserm-00636182⟩
141 Consultations
435 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More